RhumbLine Advisers
SMMT icon

RhumbLine Advisers’s Summit Therapeutics SMMT Stock Holding History

RhumbLine Advisers’s Portfolio SMMT Stock Details SMMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.85M Sell
126,895
-2,647
-2% -$46.9K ﹤0.01% 1977
2026
Q1 		$2.46M Buy
129,542
+8,201
+7% +$133K ﹤0.01% 1750
2025
Q4 		$2.12M Sell
121,341
-1,581
-1% -$29.7K ﹤0.01% 1851
2025
Q3 		$2.54M Buy
122,922
+528
+0.4% +$12.8K ﹤0.01% 1773
2025
Q2 		$2.6M Sell
122,394
-9,366
-7% -$214K ﹤0.01% 1745
2025
Q1 		$2.54M Buy
131,760
+6,558
+5% +$132K ﹤0.01% 1696
2024
Q4 		$2.23M Buy
125,202
+5,394
+5% +$105K ﹤0.01% 1831
2024
Q3 		$2.62M Sell
119,808
-8,811
-7% -$123K ﹤0.01% 1749
2024
Q2 		$1M Sell
128,619
-12,024
-9% -$64.9K ﹤0.01% 2243
2024
Q1 		$582K Buy
140,643
+6,932
+5% +$27.6K ﹤0.01% 2570
2023
Q4 		$349K Buy
133,711
+424
+0.3% +$872 ﹤0.01% 2877
2023
Q3 		$249K Buy
133,287
+6,061
+5% +$11.6K ﹤0.01% 3035
2023
Q2 		$319K Buy
+127,226
New +$232K ﹤0.01% 2968
2022
Q2 		– Sell
-15,115
Closed -$37K – 3221
2022
Q1 		$37K Buy
15,115
+2,292
+18% +$5.78K ﹤0.01% 2988
2021
Q4 		$34K Sell
12,823
-603
-4% -$2.9K ﹤0.01% 2994
2021
Q3 		$67K Buy
13,426
+908
+7% +$6.52K ﹤0.01% 3015
2021
Q2 		$93K Buy
+12,518
New +$82.1K ﹤0.01% 2970

Other funds holding SMMT

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

RhumbLine Advisers's SMMT Position: Q2 2026 in Review

RhumbLine Advisers reduced its Summit Therapeutics (SMMT) stake by 2% in Q2 2026, selling an estimated $46.9K and leaving 126,895 shares worth $1.85M. The position accounts for ﹤0.01% of the portfolio, ranked #1977.

RhumbLine Advisers first reported a position in SMMT in Q2 2021 and has held it in 17 quarters since. The position peaked at $2.62M in Q3 2024. 242 funds tracked by Wall St. Rank hold SMMT as of Q2 2026.

  • RhumbLine Advisers held 126,895 shares of Summit Therapeutics worth $1.85M as of Q2 2026.
  • RhumbLine Advisers sold 2,647 Summit Therapeutics shares in Q2 2026, an estimated $46.9K.
  • Summit Therapeutics made up ﹤0.01% of RhumbLine Advisers's portfolio in Q2 2026, its #1977 holding.
  • RhumbLine Advisers first reported a position in Summit Therapeutics in Q2 2021 and has held it in 17 quarters since.
  • RhumbLine Advisers's Summit Therapeutics position peaked at $2.62M in Q3 2024.
  • 242 funds tracked by Wall St. Rank held Summit Therapeutics as of Q2 2026.

Based on RhumbLine Advisers's 13F filing for Q2 2026, filed 12 Aug 2026.